B+
Bull case
25%
Probability
Target price
$165.67
+27.5% vs current
ATR
AptarGroupANYSE / Materials
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$140.00
+7.8% vs current
B-
Bear case
25%
Probability
Target price
$112.00
-13.8% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
+18.7
Positive
Company
-
Unavailable
Macro
+19.1
Positive
Pulse
-45.0
Negative
Sentiment proxy
+54.5
Score
AI commentary
News tone is mixed: the primary Q1 release showed strong reported sales and injectables growth but flat core sales, lower earnings and margin compression, alongside constructive Q2 guidance. Recent dividend, sustainability and conference headlines add limited operating information. No social coverage, options skew, short interest, Glassdoor data, post-print price-reaction attribution or analyst revision data are available.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-01eventCEO successionMedium impact
Gael Touya is scheduled to become CEO effective September 1, 2026. The transition is announced but execution and continuity remain monitoring points. [#SEC-8K-2026-04-30]
2026-10-16catalystQ2 2026 guidance executionMedium impact
Aptar guided to adjusted EPS of $1.32-$1.40 for Q2 2026 and expects growth across segments excluding emergency-medicine destocking, while flagging supply-chain uncertainty. [#SEC-8K-2026-04-30]
2026-10-16catalystDestocking and margin pressureMedium impact
Emergency-medicine destocking reduced Pharma prescription sales, while adjusted EBITDA margins declined year over year in Pharma, Beauty and Closures. Further weakness or delayed recovery would pressure the shares. [#SEC-8K-2026-04-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology